The 12 closest competitors and alternatives to VALERIO TX among biotech companies — ranked by similarity to what VALERIO TX actually does, not by market-cap band.
Subscribe to see VALERIO TX’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.
VALERIO TX is a biotech company headquartered in France. Xcout tracks 2 named people at VALERIO TX, including Julien Miara (Chief Executive Officer).
Ranked by semantic similarity — how close each company is to VALERIO TX by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Variant Bio, Inc. is a biotechnology company that uses human genomic diversity and population genetics to discover therapeutic targets and develop medicines. It works with researchers, healthcare and biotechnology partners, and genetically diverse communities to study traits associated with health and disease.
Similar biotech company
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Similar biotech company
Circio Holding ASA is a biotechnology company that develops novel circular RNA and immunotherapy medicines, utilizing its proprietary circVec platform to enhance gene therapy for genetic diseases. It serves the biopharmaceutical sector and patients with genetic disorders by advancing clinical programs and engaging in research collaborations.
Biotechnology
Tessellate Bio is a biotechnology company that develops precision oncology medicines by exploring synthetic lethal interactions beyond homologous recombination deficiency. The company integrates biomarker discovery and companion diagnostics into its research programs to create first-in-class treatments for hard-to-treat cancers.
Similar biotech company
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Biotechnology
Violet Therapeutics, Inc. is a therapeutics company headquartered in Cambridge, Massachusetts, utilizing novel proprietary platforms for drug development.
Biotechnology
Aro Biotherapeutics is a U.S. biotechnology company developing targeted therapeutics using its Centyrin protein platform, including delivery of genetic medicines to specific tissues and cells. It serves patients with serious diseases and partners or works with biopharmaceutical organizations to advance targeted drug-development programs.
Biotechnology
Laigo Bio is a biotechnology company that develops targeted protein degradation therapeutics using its proprietary SureTAC platform. The company utilizes bispecific antibodies to direct cell surface targets toward lysosomal degradation, primarily serving the oncology and immunology sectors.
Similar biotech company
Vesalius Therapeutics is a biotechnology company founded by Flagship Pioneering to redefine how common illnesses are treated. Headquartered in Cambridge, Massachusetts, the firm applies novel human data insights to drug discovery and therapeutic development.
Biotechnology
Parabilis Medicines is a biopharmaceutical company that develops ultra-tunable peptide therapeutics utilizing its proprietary Helicon platform. The company focuses on creating novel medicines to target historically undruggable conditions, primarily addressing cancer and other serious diseases with critical medical needs.
Biotechnology
Vibrant Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, with operations in China. Founded in July 2019, the firm focuses on revolutionizing protein drug discovery and developing next-generation prodrugs with precise targeting.
Biotechnology
DCx Biotherapeutics is a Canadian preclinical-stage biotechnology company developing precision oncology therapeutics and precision drug conjugates to target genetically defined cancers. The company focuses on addressing root drivers and key cellular interdependencies of cancer lesions.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for VALERIO TXand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →